Navigation Links
Sanguine BioSciences Signs Agreements with More than 200 Partners to Enable Efficient Personalized Medicine Research
Date:9/4/2013

VALENCIA, Calif., Sept. 4, 2013 /PRNewswire/ -- Sanguine BioSciences, a biotechnology company enabling personalized medicine research, today announced that it has signed commercial agreements with, and received orders from, more than 200 biomedical researchers at academic, biotechnology and pharmaceutical companies, to enable more efficient personalized medicine research. Ongoing agreements are in place with a wide range of organizations, ranging from startups, such as Inhibrx, to contract research organizations, such as Applied Immunology, and major drug developers, such as Vertex Pharmaceuticals.

Sanguine directly engages patients diagnosed with severe and chronic diseases to collect and de-identify biospecimen, medical history and other data that can be used in biomarker research. Traditional methods are to obtain biospecimen through hospitals, but this process can result in months of delays as the focus for physicians and staff is on diagnosis and treatment, not facilitating research efforts. By engaging patients directly, Sanguine can meet the needs of researchers and offer timely turnaround of biospecimen and medical data with diverse ranges for age, race, disease state, gender and treatments underway. The patient engagement tactics used by the company have led to a 95 percent retention rate, which also allow for follow-up draws for longitudinal studies.

"In a very short amount of time, and with only recently hiring our first few sales executives, our company has established agreements with ten of the largest drug developers in the world and continues to see high demand for our offering," said Brian Neman, founder and chief executive officer of Sanguine. "Researchers have specific needs to complete studies in early discovery work, sometimes run with blood samples drawn the same day and other times requiring follow-up draws on exact time schedules, but traditional strategies to obtain
'/>"/>

SOURCE Sanguine BioSciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sanguine BioSciences Announces Distribution Partnership with AMS Biotechnology
2. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research, Co-Invest in Sanguine BioSciences
3. INVENT Ventures and Heliant Ventures Seek to Accelerate Personalized Medicine Research with Seed Round Investment in Sanguine BioSciences
4. Sanguine Appoints Darlene Rosario, Vice President of Regulatory Affairs & Quality at Biothera, Inc., to Clinical Advisory Board and Ethics Committee
5. Rancho BioSciences Launches Rancho tranSMART Hosted for Clinical and Genomic Data Storage and Analysis
6. Former Life Technologies and BD Biosciences Executive John L. "Kip" Miller Joins Solulinks Board of Directors
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2013 Financial Results and Provide a Business Update
8. MD Biosciences Offers IL-23-Induced Psoriasis-Like Preclinical Model for Skin Inflammation
9. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
10. Flagship Biosciences Expands Digital Pathology with Pharmaceutical Biostatistics Services
11. Neurocrine Biosciences Reports Second Quarter 2013 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)...   Regulus Therapeutics Inc . (NASDAQ: ... development of innovative medicines targeting microRNAs, today announced that ... Executive Officer of Regulus, will present a company overview ... Healthcare Conference on Wednesday, March 4, 2015 at 9:20 ... Boston Marriott Copley Place.  The presentation ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3
... insertion and one-step purification from a more versatile ... and FLAG ,Epitope Tagging in E. coli ... Bauer Peter,Vaillancourt ,Stratagene , Stratagene has improved ... the new pCAL-n-FLAG vector. This new E. coli ...
... PCR-based mycoplasma detection , Douglas McKenzie ... introduces the Mycoplasma PCR Primer Set Plus, ... specifically amplifies an 874-bp,PCR product from a single ... internal,control template that serves as a positive control ...
... recover intact DNA from blood, bone marrow, and ... Mark J. Dycaico ,Stratagene , Stratagene now offers ... using the RecoverEase DNA,isolation kit. New ... and,tissue culture cells. In addition, protocols for liver, ...
Cached Biology Technology:High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 2High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 3High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 4High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 5High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 6High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 7High-Level Protein Expression, One-Column Purification, and FLAG,Epitope Tagging in E. coli 8A New PCR-based Mycoplasma Detection Method 2A New PCR-based Mycoplasma Detection Method 3A New PCR-based Mycoplasma Detection Method 4A New PCR-based Mycoplasma Detection Method 5A New PCR-based Mycoplasma Detection Method 6New Protocols for Isolating High- Molecular-Weight Genomic DNA 2New Protocols for Isolating High- Molecular-Weight Genomic DNA 3New Protocols for Isolating High- Molecular-Weight Genomic DNA 4New Protocols for Isolating High- Molecular-Weight Genomic DNA 5New Protocols for Isolating High- Molecular-Weight Genomic DNA 6New Protocols for Isolating High- Molecular-Weight Genomic DNA 7New Protocols for Isolating High- Molecular-Weight Genomic DNA 8
(Date:2/13/2015)... ACT Genomics Co., Ltd., a cancer ... cancer genomic information into precision diagnosis and personalized ... US$ 8 million in the its first private funding ... Taiwan , ACT Genomics has developed comprehensive ... to implement next generation sequencing (NGS) and multiplex ...
(Date:2/12/2015)... OXFORD, Conn. , Feb. 12, 2015 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... it has filed provisional patent 62/113114 for ... MULTIPLE DEVICES. The patent further establishes NXT-ID,s ... to its intellectual property portfolio the ability for multiple ...
(Date:2/10/2015)... Inc. (NYSE: ALR), a global leader in rapid ... ended December 31, 2014. Namal Nawana, ... "We made substantial progress in the fourth quarter ... rapid diagnostics and delivering against our financial plans.  ... January enabled us to substantially reduce our debt, ...
Breaking Biology News(10 mins):ACT Genomics Raises $8 Million in its First Private Funding Round 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33
... 2014 - Scientists at A*STAR,s Institute of Molecular and ... that sequenced and analysed the genome of the elephant ... with human and other vertebrate genomes revealed why the ... bones. The findings carry potential implications for human bone ...
... cells transfer energy by taking advantage of molecular ... classical physics, according to the first unambiguous theoretical ... in the journal Nature Communications . ... chromophores (responsible for the colour of molecules) attached ...
... much slower and live significantly longer than previously thought, according ... Institution (WHOI). In the first successful radiocarbon age validation ... females and four males from the northwestern Atlantic Ocean. Age ... male and 40 years old for the largest female. ...
Cached Biology News:Elephant shark genome provides new insights into bone formation and adaptive immunity in humans 2Elephant shark genome provides new insights into bone formation and adaptive immunity in humans 3Quantum mechanics explains efficiency of photosynthesis 2New study finds extreme longevity in white sharks 2New study finds extreme longevity in white sharks 3
Bag-1 (K-20)...
... 4 deuterium atoms at the 3, 3', ... for use as an internal standard for ... GC- or LC-mass spectrometry. PGE2 is one ... acid and one of the most widely ...
, Glycerol 30%...
Any form, any size, any number of mutageneses. ExonBio provides the best service with double sequecing to make sure the success of the mutagenesis....
Biology Products: